Piperacillin/tazobactam in the treatment of community-acquired and nosocomial respiratory tract infections: A review
- 1 July 1994
- journal article
- clinical trial
- Published by Springer Nature in Intensive Care Medicine
- Vol. 20 (3) , S21-S26
- https://doi.org/10.1007/bf01745247
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 1993
- Preventing nosocomial pneumonia: State of the art and perspectives for the 1990sThe American Journal of Medicine, 1991
- The scope of lower respiratory tract infectionInfection, 1991
- Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1991
- Piperacillin/tazobactam (YTR 830) combinationDiagnostic Microbiology and Infectious Disease, 1989
- Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactamAntimicrobial Agents and Chemotherapy, 1989
- Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanateAntimicrobial Agents and Chemotherapy, 1989